MEMPHIS, Tenn., Oct. 14, 2026 /PRNewswire/ -- International Paper (NYSE: IP; LSE: IPC), a leader in sustainable packaging solutions, announces that its EMEA Packaging Business leadership team will hold a Capital Markets Day in London on November 3, 2026, 13:00 – 17:00 GMT (8:00 a.m. – 12:00 p.m. ET).

International Paper has made significant progress preparing to separate its EMEA Packaging Business into an independent, publicly traded company (the "Separation"). Once the Separation is complete, the independent company will be known as DS Smith plc.

Tim Nicholls and Vincent Bonnot, the future Chief Executive Officer and future Chief Financial Officer of DS Smith plc, respectively, will host the Capital Markets Day, alongside other senior leaders from across the EMEA business. The team will discuss the planned public company and its position as an enhanced pure-play packaging leader within the European market. The team will also provide details about the business model, growth strategy, and financial outlook post Separation.

The event will be available via webcast, and a recording will be provided on DS Smith's website upon event completion.

To register for the webcast please visit: https://stream.brrmedia.co.uk/broadcast/6aa9548bba91570013153fcd

If you wish to attend in person, please contact [email protected].

Separation Update

DS Smith plc is expected to be separated by way of a spin off, through the listing of the business on the London Stock Exchange with a Level II ADR program to be listed on the New York Stock Exchange.

The Separation remains subject to the satisfaction of customary conditions, including final approval by the International Paper Board of Directors as well as the filing and effectiveness of a registration statement with the U.S. Securities and Exchange Commission (the "SEC") and the publication of a prospectus approved by the U.K. Financial Conduct Authority (the "FCA"). No assurance can be provided regarding the ultimate timing or structure of the proposed Separation or its eventual completion.

About International Paper (NYSE: IP; LSE: IPC)

International Paper creates sustainable packaging solutions that enable our customers, teammates and shareowners to thrive in an ever-changing world. We are a leader in corrugated packaging, partnering with customers across industries to protect what matters most, strengthen supply chains and create lasting value. Learn more at internationalpaper.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the use of forward-looking or conditional words such as "expects," "anticipates," "believes," "estimates," "could," "should," "can," "forecast," "outlook," "intend," "look," "may," "will," "remain," "confident," "commit" and "plan" or similar expressions. These forward-looking statements reflect management's current views and are subject to risks and uncertainties that could cause actual results and the timing of events to differ materially from those expressed or implied in these forward-looking statements. These risks and uncertainties include the risks that this planned Separation of the Company's North America and EMEA operations into two independent public companies will not happen on a timely basis or at all, the Company's ability to achieve the desired outcome and realize the anticipated benefits from the Separation and the potential uncertainty and disruption during the pendency of the Separation. These forward-looking statements are also subject to the risks and uncertainties contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission on February 27, 2026, and subsequent reports filed with the SEC. In addition, other risks and uncertainties not presently known to the Company or that we currently believe to be immaterial could affect the accuracy of any forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements contained in this press release, whether as a result of new information, future events or changes in expectations.

SOURCE International Paper

Share this article

MIRACELL to Host Stem Cell Science Day 2026 in Los Angeles, Featuring International Clinical Insights in Regenerative Medicine

- Leading South Korean and U.S. medical experts to share clinical insights into regenerative medicine

- Austrian clinical study on 47 ACL rupture patients treated with SMART M-CELL published in peer-reviewed journal

LOS ANGELES, Oct. 14, 2026 /PRNewswire/ -- Miracell U.S. Inc., the U.S. subsidiary of South Korean stem cell technology pioneer Miracell, will host "Stem Cell Science Day 2026," a specialized seminar on regenerative medicine, in Los Angeles, California, on Sunday, Nov. 1.

The seminar will bring together medical professionals from South Korea and the United States to present the latest research developments and clinical findings in stem cell-based therapies. Participants will explore real-world clinical applications and potential healthcare integration of Miracell's proprietary SMART M-CELL system in the U.S.

The event will take place from 1:00 p.m. to 7:00 p.m. at The Equitable Building (14th Floor) on Wilshire Boulevard in Los Angeles. It is open to healthcare professionals—including physicians (MD/DO), nurse practitioners (NP), physician assistants (PA), and registered nurses (RN)—free of charge.

Leading Medical Experts to Present Advances in Regenerative Medicine

The seminar features three prominent practitioners from South Korea and the U.S. who will present emerging research and clinical outcomes across women's health, orthopedics, and anti-aging medicine:

- Tae-hee Kim, M.D., Ph.D., Professor of Obstetrics and Gynecology at Soonchunhyang University Bucheon Hospital, will present "The Future of Women's Health and Regenerative Medicine," highlighting recent scientific breakthroughs and novel therapeutic approaches.

- Alex Kim, M.D., Director of the TIME Anti-Aging and Hair Transplant Center in the U.S., will discuss "Global Trends in Stem Cell Therapy and Regenerative Approaches in Orthopedics," drawing from his extensive clinical practice in the United States.

- Sung-Wook Choi, M.D., Ph.D., Professor of Orthopedic Surgery at Jeju National University, will share clinical cases and therapeutic applications using Miracell's SMART M-CELL stem cell isolation and concentration system.

International Study Highlights Clinical Outcomes of SMART M-CELL for ACL Injuries

Miracell's SMART M-CELL system continues to gain global academic traction. A research team led by Patrick Weninger, M.D., an orthopedic specialist in Vienna, Austria, recently published findings from a clinical study involving 47 patients with anterior cruciate ligament (ACL) ruptures (mean age: 28.1 years) in the SCIE-indexed Indian Journal of Orthopaedics (July 2026).

The study—titled "Autologous Peripheral Blood-Derived Stem Cells Combined with Platelet-Rich Plasma is Associated With Clinical and Radiological Improvement in Anterior Cruciate Ligament Ruptures—Preliminary Clinical and MRI Findings in 47 Consecutive Patients"—evaluated a non-surgical treatment combining autologous blood-derived cells and platelet-rich plasma (PRP).

Using the SMART M-CELL system, researchers isolated and concentrated CD34+-containing blood-derived stem cells (BSCs) from each patient. Combined with PRP, the preparation was administered to the injured ligament in a single non-surgical session. Over a 12-month follow-up period:

- 46 out of 47 patients successfully returned to their pre-injury sports activity levels.

- Patients demonstrated significant pain reduction, improved knee function, and positive structural restoration on MRI scans.

These findings highlight the potential of a tissue-preserving, biological approach to ACL management—offering an effective non-surgical alternative for selected patients.

U.S. Expansion and Global Collaboration

SMART M-CELL is an advanced cell separation system engineered to process autologous blood and bone marrow. In April 2026, Miracell received 510(k) clearance from the U.S. FDA for its SMART M-CELL blood-derived stem cell (BSC) and bone marrow-derived stem cell (BmSC) concentration systems and dedicated kits, establishing a solid foundation for its entry into the U.S. market.

Beyond clinical presentations, Stem Cell Science Day 2026 will feature panel discussions, interactive Q&A sessions, one-on-one consultations, and networking opportunities designed to foster long-term international collaboration in regenerative medicine.

Event Details

- Event: Stem Cell Science Day 2026

- Date: Sunday, November 1, 2026

- Time: 1:00 p.m. – 7:00 p.m. PDT (Los Angeles time)

- Venue: The Equitable Building, 14th Floor

- Address: 3435 Wilshire Blvd., Suite 1400, Los Angeles, CA 90010

- Target Audience: Physicians and Licensed Healthcare Professionals (MD, DO, NP, PA, RN)

- Admission: Free (Advance registration required; limited seating)

- Organizer: Miracell U.S. Inc.

- RSVP & Inquiries:[email protected] | +1 213-318-8839

- Website:www.mira-cell.us

SOURCE Miracell

Share this article

Altair Semiconductor Integrates Iridium NTN Direct into ALT1350 and ALT1550 Cellular IoT Chipsets

MCLEAN, Va., Oct. 14, 2026 /PRNewswire/ -- Iridium Communications Inc. (Nasdaq: IRDM), a leading provider of global voice, data, aircraft surveillance, and positioning, navigation, and timing (PNT) satellite services, today announced that Altair Semiconductor, a world leader in cellular IoT chips, is integrating Iridium NTN Direct℠ capability into Altair's ALT1350 and next-generation ALT1550 IoT chipset platforms. With terrestrial cellular IoT and Iridium satellite connectivity on a single chipset, device manufacturers, module makers and mobile network operators (MNOs) will be able to extend IoT connectivity beyond the reach of terrestrial networks through the Iridium satellite network, without adding a separate satellite modem to their designs.

The partnership combines Altair's cellular IoT chipset technology, among the most highly integrated low-power connectivity solutions available, with Iridium's 3GPP standards-based non-terrestrial network (NTN) service, giving device manufacturers another chipset option for products that need connectivity beyond terrestrial cellular coverage. With the ultra-low-power ALT1350, these connectivity requirements can include asset tracking, logistics, smart metering and utilities, agriculture, vehicle telematics, industrial monitoring and remote infrastructure. With the ALT1550, these capabilities extend to a new generation of AI-powered 5G eRedCap devices, such as smart glasses, AI assistants and other wearables, that need to stay connected wherever they go.

"Altair has deep experience developing highly integrated, low-power IoT solutions, and we're excited to work together to extend their reach with Iridium's truly global satellite network," said Tim Last, executive vice president, Iridium. "As a market leader in satellite IoT, Iridium is offering device manufacturers a powerful new way to develop connected products. Integrating Iridium NTN Direct into Altair's chipsets will enable solutions and applications that require reliable, low-power connectivity beyond the limits of terrestrial networks."

"Adding Iridium NTN Direct to our ultra-low-power LTE-M/NB-IoT ALT1350 and 5G eRedCap ALT1550 chipsets reflects our commitment to giving customers greater flexibility in how and where their IoT devices connect," said Dima Feldman, VP Product Management and Marketing, Altair Semiconductor. "With Iridium's truly global LEO satellite connectivity alongside terrestrial cellular, device manufacturers can more easily develop solutions that will reliably work anywhere they're deployed."

Iridium NTN Direct leverages Iridium's fully operational, LEO satellite constellation and globally coordinated L-band spectrum to extend standards-based connectivity beyond terrestrial networks. The service is designed to support NB-IoT and direct-to-device (D2D) applications using compatible 3GPP standards-based chipsets, providing MNOs, chipset manufacturers and device makers with a path to extend connectivity through the Iridium satellite network.

Altair joins a growing ecosystem of partners bringing the Iridium NTN Direct service to market. A combination of chipmakers, module manufacturers, OEMs, device makers, and IoT developers is leading the next generation of NTN-cellular integration with Iridium NTN Direct.

For more information about Iridium NTN Direct, visit www.iridium.com/ntn-direct

About Iridium Communications Inc.

Iridium Communications Inc. (Nasdaq: IRDM) operates the world's only truly global mobile satellite network. It serves as a platform for innovation, enabling voice, data, and messaging, positioning, navigation, and timing (PNT), and aircraft surveillance services anywhere on Earth. Through its satellite constellation and integrated capabilities like Aireon, the world's only space-based air traffic surveillance system, Iridium delivers services that support safety-focused operations across aviation, maritime, government, industrial, and consumer markets. The company is a leader in satellite Internet of Things (IoT) connectivity and is advancing direct-to-device (D2D) communications based on open standards to expand access to satellite services.

Headquartered in McLean, Virginia, Iridium innovates through an ecosystem of more than 500 technology and distribution partners, serving millions of customers worldwide. For more information visit www.iridium.com.

Forward-Looking Statements Disclosure

Statements in this press release that are not purely historical facts may constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. The company has based these statements on its current expectations and the information currently available to us. Forward-looking statements in this press release include statements regarding the capabilities, benefits and availability of the Iridium NTN Direct service. Forward-looking statements can be identified by the words "anticipates," "may," "can," "believes," "expects," "projects," "intends," "likely," "will," "to be" and other expressions that are predictions or indicate future events, trends or prospects. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Iridium to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties regarding the timing of commercial availability of the Iridium NTN Direct service, the company's ability to maintain the health, capacity and content of its satellite constellation, general industry and economic conditions, and competitive, legal, governmental and technological factors. Other factors that could cause actual results to differ materially from those indicated by the forward-looking statements include those factors listed under the caption "Risk Factors" in the company's Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on February 12, 2026, and the company's Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on July 22, 2026, as well as other filings Iridium makes with the SEC from time to time. There is no assurance that Iridium's expectations will be realized. If one or more of these risks or uncertainties materialize, or if Iridium's underlying assumptions prove incorrect, actual results may vary materially from those expected, estimated or projected. Iridium's forward-looking statements speak only as of the date of this press release, and Iridium undertakes no obligation to update or revise any forward-looking statements.

SOURCE Iridium Communications Inc.

Share this article

- Operations and supply chain executive with more than 20 years of experience spanning GMP manufacturing, global clinical and commercial supply, and gene therapy launch execution

- Former VP of Global Supply Chain and interim Chief Technical Officer at AveXis, where he built and led the global supply chain organization through the launch of Zolgensma® across more than 30 countries

- Appointment strengthens manufacturing and supply chain leadership as Nanoscope advances lead product MOGENRY™ through regulatory review toward potential global commercialization

DALLAS, Oct. 14, 2026 /PRNewswire/ -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced the appointment of Troy Short as Senior Vice President, Manufacturing and Supply Chain. In this role, Short will lead Nanoscope's GMP manufacturing, commercial supply, and global distribution strategy as the company advances toward the potential approval and launch of MOGENRY™ (sonpiretigene isteparvovec; MCO-010).

Mr. Short brings more than two decades of operations and supply chain leadership across the pharmaceutical and gene therapy industries, with particular depth in building the manufacturing and distribution capabilities required to bring genetic medicines to patients. He previously served as Vice President of Global Supply Chain at AveXis, Inc., where he built and led the global commercial supply chain organization through the launch of Zolgensma®, scaling distribution globally, including the design of the specialized cold-chain model required for patient-specific delivery. He negotiated supply agreements, managed raw material sourcing, led the enterprise resource planning system implementation, and played a leadership role in FDA licensure and commercial readiness. Following the acquisition of AveXis by Novartis, he served as interim Chief Technical Officer during the transition.

Mr. Short subsequently served as Senior Vice President of Manufacturing and Supply Chain at Jaguar Gene Therapy, where he built Jaguar's CMC and supply chain organization, internalized process and analytical development, and directed the design of their GMP manufacturing facility. He later served as Chief Operating Officer of Advanced Medicine Partners, leading the design and startup of their GMP facility. Most recently, through his firm GTxConsulting, he has advised biotechnology companies and investment firms on CMC strategy, as well as supply chain and BLA readiness for gene therapies and other advanced modalities. Earlier in his career, Mr. Short spent 11 years at Hospira, a Pfizer company, as Director of Supply Chain for sterile pharmaceutical manufacturing.

"Troy has done what very few people in our industry have done: built and run the supply chain that delivered an approved AAV gene therapy to patients around the world," said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope Therapeutics. "A one-time intravitreal therapy manufactured in the U.S. has to reach every patient who needs it, at quality, without interruption. That capability is built years in advance, and Troy knows exactly how to execute. His arrival at this stage reflects how seriously we are taking our preparation for launch."

Nanoscope continues to build clinical, regulatory, scaled-up manufacturing, and commercial-preparation momentum in support of MOGENRY for inherited retinal dystrophies (IRDs). The U.S. Food and Drug Administration (FDA) has accepted and filed the company's Biologics License Application (BLA) for MOGENRY for the treatment of retinitis pigmentosa (RP) with severe vision loss. The BLA is presently under FDA review. A Japan New Drug Application (JNDA) for MOGENRY is also currently under PMDA review for IRDs. These milestones reflect the company's expanding international regulatory pathway as it advances commercialization planning across key global markets.

"MOGENRY is designed to work regardless of the gene behind a patient's vision loss. My job is to make sure it reaches them," said Short. "My focus will be on strengthening our manufacturing partnerships, building a resilient commercial supply chain, and making sure patients and their physicians can count on product availability upon its potential approval."

About Inherited Retinal Dystrophies

Inherited retinal dystrophies (IRDs) are a genetically diverse group of rare disorders, caused by mutations in more than 250 genes, in which progressive loss of photoreceptor cells leads to impaired vision and, in most cases, complete blindness. IRDs include retinitis pigmentosa, the most common IRD, as well as Stargardt disease, cone-rod dystrophies, and Leber congenital amaurosis, among others. Because gene-specific therapies address only a single genetic cause, the vast majority of patients with IRDs have no approved treatment option.

About MOGENRY (sonpiretigene isteparvovec; MCO-010)

Nanoscope's multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope's Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team spent more than a decade evaluating its performance across multiple animal models and human diseases. MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope's MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows.

About Nanoscope Therapeutics

Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the FDA has accepted and filed the company's BLA for MOGENRY, and the PMDA has accepted for priority review the company's Japan new drug application (JNDA) for MOGENRY for the treatment of IRDs. If approved, MOGENRY has the potential to become the standard of care for patients with RP and other IRDs, administered as a one-time, in-office injection without the need for genetic testing. The company has also shown promising results in the STARLIGHT Phase 2 clinical trial (NCT05417126) of MCO-010 in Stargardt disease (SD) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with Regenerative Medicine Advanced Therapy (RMAT) designation for SD, and European Medicines Agency (EMA) Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has also received Sakigake and Orphan designations for IRDs in Japan and an Orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in geographic atrophy is expected to start in 2026, and other investigational new drug (IND)-ready programs include Leber congenital amaurosis (LCA). Learn more at NanosTherapeutics.com and follow @NSTherapeutics on X and on LinkedIn. 

Contact:

Nanoscope Therapeutics Inc.

+1 (817) 857-1186

[email protected]

SOURCE Nanoscope Therapeutics

Share this article

Company ships in-document protection that lets AI read a contract without seeing what is confidential inside it

NEW YORK, Oct. 14, 2026 /PRNewswire/ -- Cyphlens has been named a 2026 Gartner® Cool Vendor™ in "Coolest Vendor Innovations in Data Security report."

Asking AI to help with a document should not mean handing it every confidential detail inside.

You want AI to find the renewal deadline in a customer agreement. You do not want it reading the negotiated price.

Cyphlens encrypts the price inside that agreement while leaving the rest readable. AI can review the document and find the deadline, but sees a cipher where the price would be. Only an authorized person can reveal the protected information. Selected regions are replaced in place, so the file stays an ordinary Word or PDF with no encrypted container, and each region carries its own recipients. One document can disclose different things to different readers.

The capability is generally available today, applied through a Cyphlens skill for Claude.

Cyphlens also protects whole files, up to one terabyte, through the same control. Teams share them through the channels they already use. File content never touches Cyphlens servers, because CypherFile encrypts and decrypts on the sender's own devices. Senders keep control after sharing: revocation renders a copy permanently inaccessible wherever it traveled, because every open is checked before content is revealed.

"For years, security could largely assume that the person opening a document was the one reading it. That assumption no longer holds. We built Cyphlens so AI can work with the context it needs while sensitive information remains under human control," said Rocky Motwani, CEO of Cyphlens.

"As AI takes on more document-heavy workflows, security will increasingly center on granular access: what each reader, human or AI, is able to see," said Rob Keith, Partner at Salesforce Ventures. "Cyphlens is building that control layer, giving organizations governance over sensitive data even after a file leaves their hands."

AI gets the context it needs. People retain control over what becomes visible.

Learn more: https://cyphlens.com/

#DataSecurity #AISecurity #AgenticAI

Media contact: [email protected]

Source: Gartner, "Coolest Vendor Innovations in Data Security," Joerg Fritsch, Andrew Bales, Paulo Aresta, Sarah Almond and Niyati Daftary, 26 August 2026.

Gartner, COOL VENDORS™ is a trademark of Gartner Inc. and its affiliates. Gartner does not endorse any company, vendor, product, or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner's business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

SOURCE Cyphlens

Share this article

ROCKVILLE, Md., Oct. 14, 2026 /PRNewswire/ -- Ceva, Inc. (NASDAQ: CEVA), the leading licensor of silicon and software IP for the Smart Edge, will announce results for the third quarter 2026 on November 9, 2026 before the NASDAQ market opens.

Following the release, Ceva management will conduct a conference call at 8:30 a.m. Eastern Time to discuss results for the quarter and business outlook.

The conference call will be available via the following dial in numbers:

- U.S. Participants: Dial +1 844-435-0316 (Access Code: Ceva)

- International Participants: Dial +1 412-317-6365 (Access Code: Ceva)

The conference call will also be available live via webcast at the following link: https://app.webinar.net/oKLP6DwbXyv. Please go to the website at least fifteen minutes prior to the call to register.

For those who cannot access the live broadcast, a replay will be available by dialing +1 855-669-9658 or +1 412-317-0088 (access code: 7028120) from one hour after the end of the call until 9:00 a.m. (Eastern Time) on November 16, 2026. The replay will also be available at Ceva's web site at www.ceva-ip.com.

About Ceva, Inc.

Ceva powers the Smart Edge, bridging the digital and physical worlds to bring AI-driven products to life. Our Ceva AI fabric portfolio of silicon and software IP enables devices to Connect, Sense, and Infer – the essential capabilities for the intelligent edge. From 5G, cellular IoT, Bluetooth, Wi-Fi, and UWB connectivity to scalable Edge AI NPUs, AI DSPs, sensor fusion processors and embedded software, Ceva provides the foundational IP for devices that connect, understand their environment, and act in real time.

With more than 22 billion devices shipped and trusted by 400+ customers worldwide, Ceva is the backbone of today's most advanced smart edge products - from AI-infused wearables and IoT devices to autonomous vehicles and 5G infrastructure. Our differentiated solutions deliver seamless integration into existing design flows, total flexibility to combine solutions based on design needs and ultra‑low‑power performance in minimal silicon footprint, helping customers accelerate development, reduce risk, and bring innovative products to market faster. As technology evolves toward Physical AI, Ceva's IP portfolio lays the foundation for systems that are always connected, contextually aware, and capable of intelligent, real-time decision-making.

Visit us at www.ceva-ip.com and follow us on LinkedIn, X, YouTube, Facebook, and Instagram.

https://mma.prnewswire.com/media/74483/ceva__inc__logo.jpg

SOURCE Ceva, Inc.

Share this article

Backed by $10 million in venture capital, Bind AI automates the entire process from quote to bind so insurance brokers can spend their time with clients

NEW YORK, Oct. 14, 2026 /PRNewswire/ -- Bind AI today announced its public launch as the AI workforce for insurance. The company, which is already live with hundreds of insurance agencies and touching billions of dollars in commercial premium, automates submission intake, quoting, proposals and binding on brokers' behalf. Bind AI has raised $10 million in funding from Bonfire Ventures and other leading VCs to date.

Agents and brokers sell roughly 90% of business insurance in the United States, yet spend only about 10% of their time with clients. The rest is lost to paperwork: rekeying submissions, chasing carriers for quotes, assembling proposals and processing binds. Bind AI does that work autonomously and delivers the outcome from quote to bind, saving agencies hundreds of hours per month.

Instead of being a standalone platform, Bind AI is the only solution in the market that integrates directly with where agents spend the most time: their inbox. Bind AI processes every inbound email and document, recognizes what needs to happen and does it before the agent even has to ask. Instead of requiring agents to change their behavior and learn a new portal, Bind AI simply sends them the completed work for their review.

"Agents and brokers didn't get into insurance to do data entry, but that's where their days go," said Tony Marshi, founder of Bind AI. "We built Bind AI to be the AI teammate that handles the work no one wants to do, so brokers can be in front of clients instead of behind a screen. The hundreds of agencies live on Bind AI today are proof that when you deliver outcomes instead of tools, brokers adopt fast."

In addition to email, Bind AI works directly inside the quoting portals where agents spend the majority of their days. Bind AI has already quoted hundreds of millions in premium across major carriers, helping agents win and retain millions in commercial business.

The $10 million in fundraising has contributed to Bind AI's rapid expansion across agencies and brokerages nationwide, along with the growth of its team in New York. Other investors include Ramp Co-Founder Karim Atiyeh and Draper Associates.

"Building AI-powered, service-as-software solutions to modernize legacy workflows in the insurance vertical is one of today's most exciting opportunities," said Jim Andelman, Bonfire Ventures Co-Founder and Managing Director. "Bind AI has already built impressive momentum and is poised to revolutionize this trillion-dollar market.

Bind AI is available today to insurance agencies and brokers. To learn more or request a demo, visit bind.ai.

About Bind AI

Bind AI is building the AI workforce for insurance, starting with agents and brokers. By integrating natively with agencies' email systems, Bind AI handles submission intake, quoting, proposals, servicing and binding, then delivers the finished work back to the agent. Headquartered in New York, Bind AI is live with hundreds of agencies representing billions in commercial premium and is backed by leading VCs. Learn more at bind.ai.

SOURCE Bind AI

Share this article

DALLAS, Oct. 14, 2026 /PRNewswire/ -- XTI Aerospace, Inc. (Nasdaq: XTIA) ("XTI Aerospace," "XTI" or the "Company"), an aerospace and advanced technology platform and parent company of Drone Nerds, LLC, ("Drone Nerds"), a leading drone solutions platform serving commercial, enterprise and government customers, today announced the appointment of Dr. Allan Evans as a director and Chairman of its Board of Directors. His addition returns the Board to five members. In connection with Dr. Evans' appointment as Chairman, the Board designated Mr. Ornstein as Vice Chairman of the Board.

"We are very pleased to welcome Allan to XTI's Board," said Jonathan Ornstein, XTI Aerospace's Vice Chairman. "Allan brings deep engineering expertise, proven business development and corporate strategy experience, as well as a firsthand understanding of the domestic supply chain for the growing U.S. drone industry. We look forward to leveraging his experience at Unusual Machines as we seek to help advance the next generation of unmanned operations across complex environments."

Dr. Evans, age 43, currently serves as Chief Executive Officer and a director of Unusual Machines, Inc. (NYSE American: UMAC), positions he has held since December 2023. From 2021 to 2023 he was Chief Operating Officer of Red Cat Holdings, Inc., a drone technology company and previously served as Chief Executive Officer of Fat Shark from 2017 until its acquisition by Red Cat in 2020. Dr. Evans received his PhD in Electrical Engineering from the University of Michigan.

Jeremy Schneiderman, Interim CEO, added, "XTI Aerospace and Drone Nerds are well‑positioned to expand our leadership in the U.S. enterprise drone market, and Allan's industry expertise, relationships, and strategic insight will be invaluable as we capitalize on that opportunity."

"I am excited to work with Jeremy, XTI's board, and the entire executive team as we focus on leveraging the Company's leadership position in the U.S. drone market during this critical transition away from foreign manufacturers," said Dr. Evans. "We have a unique opportunity to dramatically grow the business and drive meaningful outcomes for our partners and shareholders."

About XTI Aerospace, Inc.

XTI Aerospace, Inc. ("XTI") (Nasdaq: XTIA) is focused on building a leading platform for commercial and government drone adoption in the growing unmanned aircraft systems ("UAS") industry. Through its subsidiary, Drone Nerds, LLC, XTI supports enterprise and government customers in sectors including public safety, agriculture, construction, and energy across the drone program lifecycle, from hardware sourcing and deployment to training, service, repair, and the proprietary Always Flying™ program. Its established U.S. customer base and reputation as a trusted solutions provider position the company as a go-to-market partner for drone manufacturers and software developers seeking to scale in the domestic market.

For more information about XTI, please visit xtiaerospace.com and follow XTI on LinkedIn, Instagram, X, and YouTube.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release that are not historical facts (including any statements concerning plans and objectives of management for future operations or economic performance, or assumptions or forecasts related thereto) are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," "poised," "positioned," "potential," "seem," "seek," "future," "outlook," "target," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements in this press release include, without limitation, statements regarding Dr. Evans' expected contributions, the Company's market position and growth opportunities, and trends in customer demand for domestically manufactured and NDAA-compliant drones. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including Drone Nerds' reliance on DJI and other foreign suppliers, U.S. regulatory restrictions affecting foreign-manufactured drones and components, and the Company's ability to execute its strategy. For additional risks, see "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its subsequent filings with the Securities and Exchange Commission. The risks and uncertainties above are not exhaustive, and there may be additional risks that XTI presently does not know or that XTI currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect XTI's expectations, plans or forecasts of future events and views as of the date of this press release. XTI anticipates that subsequent events and developments will cause XTI's assessments to change. However, while XTI may elect to update these forward-looking statements at some point in the future, XTI specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing XTI's assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements contained in this press release.

Contacts:

General inquiries:

Email: [email protected]

Web: https://xtiaerospace.com/contact

Investor Relations:

[email protected]

SOURCE XTI Aerospace, Inc.

Share this article

DELRAY BEACH, Fla., Oct. 14, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the pet food ingredients market is estimated to be USD 41.55 billion in 2026 and is projected to reach USD 57.68 billion by 2031, at a CAGR of 6.8% from 2026 to 2031.

Pet Food Ingredients Market Size & Forecast

- Market Size Available for Years: 2022–2031

- 2026 Market Size: USD 41.55 billion

- 2031 Projected Market Size: USD 57.68 billion

- CAGR (2026–2031): 6.8%

Pet Food Ingredients Market Trends & Insights:

- The pet food ingredients market is experiencing substantial growth. This is primarily driven by rising pet ownership and pet humanization, increasing demand for premium and functional pet food, a growing focus on pet health and nutrition, and the expanding use of proteins, fibers, vitamins, minerals, palatants, and other specialty ingredients across pet food, treats, and supplements.

- The Asia Pacific region is estimated to account for 21.8% of the pet food ingredients market in 2026.

- By source, the animal-based segment is estimated to lead the market with a share of 53.8% in 2026.

- By form, the dry segment is projected to witness a higher CAGR of 7.0% from 2026 to 2031.

- By ingredient, the meat & meat products segment is expected to hold a dominant market share during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=147

The demand for pet food ingredients is increasing across dry food, wet food, treats, supplements, and specialized diets, supported by growing pet humanization and increasing consumer focus on pet health, nutrition, wellness, and preventive care. In dry and wet pet food, ingredients such as animal proteins, plant proteins, fats and oils, grains, functional carbohydrates, vitamins, minerals, and fibers are used to provide balanced nutrition, while functional ingredients such as probiotics, prebiotics, enzymes, omega-3 fatty acids, antioxidants, and specialty proteins are increasingly incorporated to support digestive health, immunity, skin and coat health, healthy aging, and overall well-being. Demand for natural, clean-label, sustainably sourced, highly digestible, and functional ingredients is also increasing as pet owners seek greater transparency and nutritional benefits. At the same time, advances in fermentation, protein processing, algae cultivation, enzyme technology, stabilization, and formulation are enabling ingredient suppliers to develop more specialized, sustainable, and application-specific solutions, further expanding the use of innovative ingredients across the pet food industry.

By source, animal-based segment to exhibit fastest growth rate during forecast period.

Animal-based ingredients are expected to be the fastest-growing source segment in the pet food ingredients market during the forecast period, driven by the increasing shift toward premiumization, specialized nutrition, and biologically targeted formulations. Pet food manufacturers are increasingly incorporating animal-derived ingredients to differentiate products through higher meat inclusion, novel protein sources, functional animal ingredients, and species-specific formulations. The expansion of fresh, refrigerated, freeze-dried, air-dried, and minimally processed pet food is creating additional opportunities for meat, poultry, fish, egg, and other animal-derived ingredients. Growing interest in novel and alternative animal proteins, including insect and marine-based sources, is also broadening the ingredient base while addressing sustainability and supply-chain considerations. Furthermore, advances in processing and ingredient preservation are enabling suppliers to maintain nutritional quality and improve the functionality of animal-derived ingredients, supporting their adoption in premium foods, treats, and specialized diets.

By ingredient, vegetables & fruits segment to record highest CAGR during forecast period.

By ingredient, the vegetables & fruits segment is expected to witness the fastest growth in the pet food ingredients market during the forecast period, driven by increasing demand for natural, functional, and nutrient-rich ingredients in pet diets. Pet owners are increasingly seeking formulations that include recognizable whole-food ingredients, while vegetables and fruits provide dietary fiber, vitamins, minerals, antioxidants, and other phytonutrients that can complement animal-based proteins and support digestive health and overall wellness. Their use is also increasing in premium, natural, fresh, and holistic pet food formulations, where ingredient transparency and clean-label positioning are important purchasing considerations. In addition, growing interest in functional nutrition is encouraging the incorporation of specific fruits and vegetables to support areas such as digestive health, immune function, and healthy aging, while improvements in ingredient processing and preservation are enabling manufacturers to incorporate these ingredients into dry food, wet food, treats, and specialized diets.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=147

Asia Pacific to be fastest-growing regional market for pet food ingredients during forecast period.

Asia Pacific is expected to be the fastest-growing region in the pet food ingredients market, supported by rapid growth in pet ownership and increasing spending on companion animals, particularly in China, India, Japan, South Korea, and Southeast Asia. In China, rising demand for premium and functional pet foods is driving the use of high-quality proteins, vitamins, minerals, probiotics, prebiotics, and omega-3 fatty acids, while India is witnessing expanding pet ownership, urbanization, and growth of organized pet food channels. Japan and South Korea have mature pet-care markets with strong demand for specialized, age-specific, and health-oriented nutrition. Across the region, pet humanization, rising disposable incomes, urban lifestyles, e-commerce penetration, premiumization, growing awareness of pet health, expansion of local pet food manufacturers, and increasing demand for sustainable and alternative ingredients are key factors accelerating the pet food ingredients market.

Top Companies in the Pet Food Ingredients Market

The report profiles key players such as BASF SE (Germany), Darling Ingredients Inc. (US), Cargill, Incorporated (US), Ingredion (US), dsm-firmenich (Netherlands), International Flavors & Fragrances Inc. (US), ADM (US), Kemin Industries, Inc. (US), Novonesis Group (Denmark), Roquette Frères (France), The Scoular Company (US), Symrise (Germany), Mowi Nutrition (Norway), Lallemand Inc. (Canada), Phileo by Lesaffre (France), and others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=147

Investment Funding Context

Investment activity in the pet food ingredients market is supporting capacity expansion, manufacturing scale-up, and the development of next-generation nutritional solutions. In October 2023, ADM invested USD 33 million to establish a new pet food production line in Guadalajara, Jalisco, increasing its manufacturing capacity and supporting the expansion of its Ganador and Minino pet food brands. In November 2021, Petsource (US), a subsidiary of the Scoular Company (US), announced a USD 75 million investment to enhance its pet food ingredient portfolio and expand its production capacities. More recently, in April 2026, Symrise made a strategic equity investment in Bond Pet Foods to advance precision-fermentation technology for animal-identical proteins and accelerate the commercialization of sustainable ingredients for pet nutrition. These investments indicate increasing industry focus on expanding production capacity, improving processing capabilities, developing alternative and functional proteins, strengthening supply-chain resilience, and supporting sustainable pet food formulations.

Revenue Shift Context

The pet food ingredients market is shifting from conventional commodity ingredients toward higher value, functional, specialty, and differentiated ingredient solutions, supported by rising demand for premium, natural, clean label, sustainable, and nutritionally optimized pet food. Market spending is projected to increase from USD 41.55 billion in 2026 to USD 57.68 billion by 2031, at a CAGR of 6.8%, with growth increasingly driven by value-added ingredients such as meat & meat products, cereals, vegetables & fruits, fats, and additives that provide targeted benefits related to pet health, digestion, immunity, and overall well-being. This shift indicates that value growth is supported not only by increasing pet food consumption but also by premiumization, pet humanization, greater adoption of functional nutrition, and increasing use of differentiated and sustainably sourced ingredients at the ingredient level.

Mergers and Acquisitions

Key players have pursued acquisitions to strengthen their presence across the pet food ingredients value chain, expand ingredient portfolios, and enhance production and processing capabilities. In 2024, Darling Ingredients acquired Miropasz Group in Poland, strengthening its supply of animal-derived raw materials for proteins, meals, and pet food ingredients, while in 2023, the Scoular Company acquired Northwest Farm Food Cooperative's frozen fish processing plant to expand its capabilities in producing fish ingredients for pet food manufacturers. ADM acquired South Sunrays Milling Corporation in the Philippines, while Symrise acquired Wing Pet Food in China to strengthen their portfolio of pet food solutions.

NORTH CANTON, Ohio, Oct. 14, 2026 /PRNewswire/ -- The Timken Company (NYSE: TKR; www.timken.com), a leader in advanced motion technology, will release its 2026 third-quarter financial results on Wednesday, November 4, prior to the opening of the New York Stock Exchange. The company will host a conference call that day to discuss its financial performance with investors and securities analysts. The financial results and conference call materials will be available online at http://investors.timken.com.

About The Timken Company

The Timken Company (NYSE: TKR; www.timken.com), a leader in advanced motion technology, designs and manufactures highly engineered systems and components for customers in strategic end markets, including aerospace and defense, power and electrification, and automation and industrial solutions. With more than 125 years of specialized expertise and a multinational presence, Timken is a trusted partner worldwide, innovating and powering performance across the application lifecycle. The company posted $4.6 billion in sales in 2025 and employs approximately 19,000 people, operating from 45 countries. Learn more at www.timken.com or @TheTimkenCompany.

Media Relations:

Sarah Factor

234.262.4878

sarah.factor@timken.com

Investor Relations:

Neil Frohnapple

234.262.2310

[email protected] 

SOURCE The Timken Company

Share this article